Merck (MRK) Payables (2009 - 2026)

Merck has disclosed Payables across 18 years of filings, most recently posting $6.0 billion for Q1 2026.

• In Q1 2026, Payables rose 2.47% year-over-year to $6.0 billion; the TTM figure through Mar 2026 stood at $6.0 billion (up 2.47% YoY), while the FY2025 annual figure was $6.5 billion, up 6.18% from the prior year.
• Payables slipped to $6.0 billion in Q1 2026, from $6.5 billion in the prior quarter.
• Over the last five years, Payables for MRK reached as high as $6.5 billion in Q4 2025 and fell as low as $5.1 billion in Q3 2022.
• The 5-year median for Payables is $5.6 billion (2023), against an average of $5.7 billion.
• Annual changes were most pronounced in 2022 — Payables dropped 5.56% — and 2025, when it gained 11.15%.
• A 5-year view of Payables shows it stood at $6.1 billion in 2022, then retreated by 3.92% to $5.9 billion in 2023, then rose by 4.33% to $6.2 billion in 2024, then climbed by 6.18% to $6.5 billion in 2025, then slipped by 8.22% to $6.0 billion in 2026.
• According to Business Quant data, Payables over the past three periods registered $6.0 billion, $6.5 billion, and $6.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.